CHMP backs Joenja for rare immune disorder APDS in Europe

Pharming has cleared an important regulatory hurdle in Europe for Joenja (leniolisib), reporting that the EMA’s CHMP adopted a positive opinion recommending marketing authorization for APDS in adults and pediatric patients ages 12 and older on March 27, 2026. The recommendation sets up a final European Commission decision in Q2 2026 and would position Joenja as the first approved therapy for APDS in the EU if cleared. Joenja is already approved in the U.S., where Pharming won FDA clearance in March 2023 for patients 12 and older, and the company has also reported approvals in the U.K. and Japan. (stocktitan.net)

The positive opinion also closes a chapter on a review that had become unusually drawn out. In May 2024, Pharming said CHMP had affirmed the positive clinical benefit and safety of leniolisib, but left one unresolved manufacturing issue related to regulatory starting materials. The agency required that work to be completed before approval and granted the company until January 2026 to respond. That means the latest CHMP action appears to reflect resolution of a chemistry, manufacturing, and controls issue rather than a new concern about efficacy or safety. That’s an inference from the regulatory timeline, but it is consistent with Pharming’s prior disclosures and the current recommendation. (pharming.com)

APDS is a rare inherited immune disorder caused by overactivation of PI3Kδ signaling, which disrupts normal B- and T-cell development and leaves patients vulnerable to recurrent infections and immune dysfunction. EMA orphan-designation documents describe the condition as long-term, debilitating, and life-threatening, with repeated lung infections that can progress to bronchiectasis. At the time of orphan designation, the EMA estimated APDS affected about 0.01 in 10,000 people in the EU, or around 500 patients, underscoring both the rarity of the condition and the limited commercial but high clinical stakes of bringing a targeted therapy to market. (ema.europa.eu)

The clinical package behind Joenja has been building for several years. In the pivotal phase 3 trial published in Blood, 31 patients ages 12 and older were randomized 2:1 to leniolisib or placebo for 12 weeks. According to the publication and Pharming’s latest summary, the study showed statistically significant improvements in co-primary measures tied to immune dysregulation and immunodeficiency, while treatment-related adverse events were mostly grade 1 or 2. Pharming also highlighted supportive long-term open-label extension data from 37 patients with a median of about three years of exposure. Additional published follow-up has suggested durable benefit over longer periods in some patients. (pubmed.ncbi.nlm.nih.gov)

As for outside perspective, Pharming’s release included a comment from Virgil Dalm, MD, PhD, of Erasmus University Medical Center, who said the leniolisib clinical program has shown “consistent, meaningful improvements” across markers of immune dysregulation and immune deficiency in APDS and called the CHMP opinion a milestone for patients in Europe. Independent expert reaction specifically to the March 2026 opinion was limited in readily available sources, but recent health-technology and outcomes literature has also framed leniolisib as a value-added option versus standard care in APDS, reflecting growing acceptance of the drug’s role in a disease with few alternatives. (live.euronext.com)

Why it matters: For veterinary professionals, this is mainly a marker of how precision immunology is moving into even very small patient populations, with regulators increasingly willing to back targeted therapies when the disease biology is clear and the unmet need is high. While APDS is a human indication, the broader signal is relevant across specialty medicine: rare-disease markets are becoming more dependent on genetic diagnosis, long-term registry data, and highly specific pathway-based treatments. It’s also a reminder that manufacturing and CMC issues can still be decisive, even after clinical questions are largely settled. (pharming.com)

There’s also a commercial and access angle. Pharming has already secured a positive NICE recommendation for Joenja in England and Wales for patients 12 and older, which suggests the company has been laying groundwork for broader European uptake ahead of a formal EU decision. At the same time, the company’s pediatric expansion plans remain mixed: the FDA issued a Complete Response Letter in February 2026 for the 4-to-11-year-old U.S. filing, despite previously granting priority review. That split picture, progress in Europe for ages 12 and older, but additional work in younger children, will matter for referral centers and pet parents following rare-disease access timelines in multi-age populations. (pharming.com)

What to watch: The immediate milestone is the European Commission’s final decision, expected in Q2 2026; after that, the practical questions will be country-level reimbursement, launch sequencing, and whether Pharming can convert its broader pediatric data into approvals for younger children after the recent U.S. setback. (stocktitan.net)